794466-70-9

Basic information

• Product Name: Vemakalant
• Synonyms: Vemakalant;Vernakalant;Vernakalant Impurity B ((3S, 1'R, 2'R)-Isomer)
• CAS NO: 794466-70-9
• Molecular Formula: C₂₀H₃₁NO₄
• Molecular Weight: 349.46444
• Mol File: 794466-70-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 479.0±45.0 °C(Predicted)
• Appearance: /
• Density: 1.14±0.1 g/cm3(Predicted)
• PKA: 14.79±0.20(Predicted)
• CAS DataBase Reference: Vemakalant(CAS DataBase Reference)
• NIST Chemistry Reference: Vemakalant(794466-70-9)
• EPA Substance Registry System: Vemakalant(794466-70-9)

Safety Data

• Hazardous Substances Data: 794466-70-9(Hazardous Substances Data)

Usage

Pharmacological action

Venakaran works by blocking peak sodium currents by blocking overdrive-activated delayed rectifier currents (IKur). IKur, encoded by the Kv1.5 channel protein, is abundantly expressed in atrial myocytes, is the main current mediating atrial repolarization in humans, and is activated during atrial fibrillation. Venakalan inhibition of IKur can prolong the action potential duration of the atrium, thereby prolonging the atrial effective refractory period and slowing down atrial conduction, so as to shorten the time of atrial fibrillation and quickly achieve the effect of atrial fibrillation conversion.

Description

Vernakalant is a potassium channel blocker that was approved in Europe in 2010 for treatment of atrial fibrillation (AF), a condition of cardiac arrhythmia in which the atria of the heart beat irregularly due to changes in cardiac ion channel function and distribution. Vernakalant has activity for cardiac Na+ and K+ channels and also for the atrial-selective Kv1.5 channel. Vernakalant (RSD1235) was characterized in animal models to assess efficacy, atrial selectivity, and reduction in side effects.

Originator

Cardiome Pharma Corp. (Canada)

Brand name

Brinavess

Upstream product

• 867152-08-7 2-(3,4-dimethoxyphenyl)ethyl 2,2,2-trichloroethanimidate 
• 134108-76-2 (1R,2R)-2-hydroxycyclohexylcarbamic acid benzyl ester 
• 931-15-7 (1R,2R)-2-aminocyclohexanol 
• 1360617-31-7 2-(3,4-dimethoxyphenyl ethoxy)-cyclohexanone 
• 906802-49-1 C₁₆H₂₄O₄ 
• 19398-47-1 (R)-1,4-dibromo-2-butanol 
• 79413-93-7 (R)-4-bromo-1,2-butylene epoxide 
• 822-87-7 2-Chlorocyclohexanone 
• 7417-21-2 2-(3,4-dimethoxyphenyl)ethyl alcohol 
• 1370354-69-0 C₂₇H₃₅NO₅ 
• 1370354-67-8 C₃₃H₅₁NO₅Si 
• 795282-03-0 C₂₂H₃₃NO₅ 
• 906802-36-6 (3R)-1-(2-(3,4-dimethoxyphenethoxy)cyclohexyl)-2,5-dioxopyrrolidin-3-yl acetate 
• 795281-92-4 (3R)-3-benzyloxy-1-{(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl}pyrrolidine 

Downstream Products

• 748810-28-8 Vernakalant hydrochloride 

Relevant articles and documents

A method for preparing weinaweina kalland hydrochloride (by machine translation)

The invention discloses a method for preparing weinaweina kalland hydrochloride. The method to selectively amino protection, nucleophilic addition, nucleophilic substitution, deprotected, cyclized, reduction, into a salt by the reaction of the compound Wina carland hydrochloride. And after nuclear magnetic analysis test technology confirm its structure. It adopts the cheap and easily obtained starting materials to prepare, preparation method has advantages of simple operation, mild condition, easy industrialized production and the like, and avoids the use of heavy metal, is beneficial to the development of the oral. (by machine translation)

PROCESS FOR PREPARATION OF AMINOCYCLOHEXYL ETHERS AND INTERMEDIATE PRODUCTS USED IN THE PROCESS

A process for preparation of a compound of formula (I) or or a pharmaceutically acceptable salt, ester, or prodrug thereof, is disclosed. The process involves hydrogenating, in the presence of a catalyst, a compound of formula (II). The different substituents are as described in the specification. Also disclosed are intermediates and processes for their preparation. Further, the process can provide an alternate route for the synthesis of Vernakalant from starting materials that can be readily available.

SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS

Methods for the preparation of stereoisomerically substantially aminocyclohexyl ether compounds such as trans-(1R,2R)-aminocyclohexyl ether compounds and/or trans-(1S,2S)-aminocyclohexyl ether compounds as well as various intermediates and substrates are disclosed.